biotech · Choroideremia · X-Linked Retinitis Pigmentosa · FDMT
4D Molecular Therapeutics
4D Molecular Therapeutics is a biotech organization headquartered in Emeryville, USA. It trades on NYSE under ticker FDMT. Primary therapeutic focus areas include Choroideremia, X-Linked Retinitis Pigmentosa, Macular neo
5858 Horton St, 455, Emeryville, California 94608, US HQ
2013 Founded
213 Employees
Public company Type
FDMT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 5858 Horton St, 455, Emeryville, California 94608, US
- Founded
- 2013
- Employees
- 213
- Programs
- 19
- Drugs
- 13
- Patents
- 15
4D-150 IVT (3E10 vg/eye)
Phase 3 · mab · Neovascular Age-Related Macular Degeneration (nAMD)
4D-150 IVT (3E10 vg/eye) for Neovascular Age-Related Macular Degeneration (nAMD) is a Phase 3 program (mab) at 4D Molecular Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code 4D-150-C004
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- 4D Molecular Therapeutics
- Phase
- Phase 3
- Modality
- mab
- Indication
- Neovascular Age-Related Macular Degeneration (nAMD)
- Status
- active
- Trials
- 1